Merozoite surface protein-1 of Plasmodium yoelii fused via an oligosaccharide moiety of cholera toxin B subunit glycoprotein expressed in yeast induced protective immunity against lethal malaria infection in mice

Vaccine

Volumn 30, Issue 5, 2012, Pages 948-958

  Miyata, Takeshi ^a   Harakuni, Tetsuya ^a   Taira, Toki ^a   Matsuzaki, Goro ^a   Arakawa, Takeshi ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

CTB; Delivery system; Malaria; Subunit vaccine

Indexed keywords

CHOLERA TOXIN B SUBUNIT; GLYCOPROTEIN; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; OLIGOSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHEMICAL ANALYSIS; DRUG EFFICACY; FEMALE; IMMUNIZATION; IMMUNOGENICITY; MALARIA; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PARASITEMIA; PLASMODIUM YOELII; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRUCTURE ANALYSIS; SURVIVAL RATE; YEAST;

ADMINISTRATION, INTRANASAL; ANIMALS; CHOLERA TOXIN; DISEASE MODELS, ANIMAL; FEMALE; GLYCOPROTEINS; INJECTIONS, SUBCUTANEOUS; MALARIA; MALARIA VACCINES; MEROZOITE SURFACE PROTEIN 1; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PICHIA; PLASMODIUM YOELII; SURVIVAL ANALYSIS; VACCINES, CONJUGATE; VACCINES, SYNTHETIC;

EID: 84855463179     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.059     Document Type: Article

References (36)

1. De S.N. Enterotoxicity of bacteria-free culture-filtrate of Vibrio cholerae. Nature 1959, 183(May (4674)):1533-1534.
2. Finkelstein R.A., Jehl J.J., Goth A. Pathogenesis of experimental cholera: choleragen-induced rat foot edema; a method of screening anticholera drugs. Proc Soc Exp Biol Med 1969, 132(December (3)):835-840.
3. Sanchez J., Holmgren J. Cholera toxin structure, gene regulation and pathophysiological and immunological aspects. Cell Mol Life Sci: CMLS 2008, 65(May (9)):1347-1360.
4. Svennerholm A.M., Jertborn M., Gothefors L., Karim A.M., Sack D.A., Holmgren J. Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine. J Infect Dis 1984, 149(June (6)):884-893.
5. Pearson G.D., Mekalanos J.J. Molecular cloning of Vibrio cholerae enterotoxin genes in Escherichia coli K-12. Proc Natl Acad Sci USA 1982, 79(May (9)):2976-2980.
6. Gennaro M.L., Greenaway P.J., Broadbent D.A. The expression of biologically active cholera toxin in Escherichia coli. Nucleic Acids Res 1982, 10(August (16)):4883-4890.
7. Lebens M., Johansson S., Osek J., Lindblad M., Holmgren J. Large-scale production of Vibrio cholerae toxin B subunit for use in oral vaccines. Biotechnology (NY) 1993, 11(December (13)):1574-1578.
8. Sanchez J., Holmgren J. Recombinant system for overexpression of cholera toxin B subunit in Vibrio cholerae as a basis for vaccine development. Proc Natl Acad Sci USA 1989, 86(January (2)):481-485.
9. Ichikawa Y., Yamagata H., Tochikubo K., Udaka S. Very efficient extracellular production of cholera toxin B subunit using Bacillus brevis. FEMS Microbiol Lett 1993, 111(August (2-3)):219-224.
10. Goto N., Maeyama J., Yasuda Y., Isaka M., Matano K., Kozuka S., et al. Safety evaluation of recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant. Vaccine 2000, 18(April (20)):2164-2171.
11. Song H., Zhou L., Fang W., Li Y., Wang X., Fang H., et al. High-level expression of codon optimized foot-and-mouth disease virus complex epitopes and cholera toxin B subunit chimera in Hansenula polymorpha. Biochem Biophys Res Commun 2004, 315(February (1)):235-239.
12. Harakuni T., Sugawa H., Komesu A., Tadano M., Arakawa T. Heteropentameric cholera toxin B subunit chimeric molecules genetically fused to a vaccine antigen induce systemic and mucosal immune responses: a potential new strategy to target recombinant vaccine antigens to mucosal immune systems. Infect Immun 2005, 73(September (9)):5654-5665.
13. Arakawa T., Chong D.K., Langridge W.H. Efficacy of a food plant-based oral cholera toxin B subunit vaccine. Nat Biotechnol 1998, 16(March (3)):292-297.
14. Nochi T., Takagi H., Yuki Y., Yang L., Masumura T., Mejima M., et al. Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination. Proc Natl Acad Sci USA 2007, 104(June (26)):10986-10991.
15. Matsumoto Y., Suzuki S., Nozoye T., Yamakawa T., Takashima Y., Arakawa T., et al. Oral immunogenicity and protective efficacy in mice of transgenic rice plants producing a vaccine candidate antigen (As16) of Ascaris suum fused with cholera toxin B subunit. Transgenic Res 2009, 18(April (2)):185-192.
16. George-Chandy A., Eriksson K., Lebens M., Nordstrom I., Schon E., Holmgren J. Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen-presenting cells. Infect Immun 2001, 69(September (9)):5716-5725.
17. Miyata T., Harakuni T., Tsuboi T., Sattabongkot J., Kohama H., Tachibana M., et al. Plasmodium vivax ookinete surface protein Pvs25 linked to cholera toxin B subunit induces potent transmission-blocking immunity by intranasal as well as subcutaneous immunization. Infect Immun 2010, 78(September (9)):3773-3782.
18. Liljeqvist S., Stahl S., Andreoni C., Binz H., Uhlen M., Murby M. Fusions to the cholera toxin B subunit: influence on pentamerization and GM1 binding. J Immunol Methods 1997, 210(December (2)):125-135.
19. Holmgren J., Adamsson J., Anjuere F., Clemens J., Czerkinsky C., Eriksson K., et al. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol Lett 2005, 97(March (2)):181-188.
20. Powers D.B., Amersdorfer P., Poul M., Nielsen U.B., Shalaby M.R., Adams G.P., et al. Expression of single-chain Fv-Fc fusions in Pichia pastoris. J Immunol Methods 2001, 251(May (1-2)):123-135.
21. Trucksis M., Conn T.L., Fasano A., Kaper J.B. Production of Vibrio cholerae accessory cholera enterotoxin (Ace) in the yeast Pichia pastoris. Infect Immun 1997, 65(December (12)):4984-4988.
22. Hardy E., Martinez E., Diago D., Diaz R., Gonzalez D., Herrera L. Large-scale production of recombinant hepatitis B surface antigen from Pichia pastoris. J Biotechnol 2000, 77(February (2-3)):157-167.
23. Zou L., Miles A.P., Wang J., Stowers A.W. Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trials. Vaccine 2003, 21(April (15)):1650-1657.
24. De Rycke J., Oswald E., Boivin R. An in vivo assay for the detection of cytotoxic strains of Escherichia coli. Ann Rech Vet 1989, 20(1):39-46.
25. Miyata T., Harakuni T., Tsuboi T., Sattabongkot J., Ikehara A., Tachibana M., et al. Tricomponent immunopotentiating system as a novel molecular design strategy for malaria vaccine development. Infect Immun 2011, 79(October (10)):4260-4275.
26. Shakin-Eshleman S.H., Spitalnik S.L., Kasturi L. The amino acid at the X position of an Asn-X-Ser sequon is an important determinant of N-linked core-glycosylation efficiency. J Biol Chem 1996, 271(March (11)):6363-6366.
27. Gavel Y., von Heijne G. Sequence differences between glycosylated and non-glycosylated Asn-X-Thr/Ser acceptor sites: implications for protein engineering. Protein Eng 1990, 3(April (5)):433-442.
28. Tarentino A.L., Gomez C.M., Plummer T.H. Deglycosylation of asparagine-linked glycans by peptide:N-glycosidase F. Biochemistry (Mosc) 1985, 24(August (17)):4665-4671.
29. Gemmill T.R., Trimble R.B. Overview of N- and O-linked oligosaccharide structures found in various yeast species. Biochim Biophys Acta 1999, 1426(January (2)):227-237.
30. Grinna L.S., Tschopp J.F. Size distribution and general structural features of N-linked oligosaccharides from the methylotrophic yeast, Pichia pastoris. Yeast 1989, 5(March-April (2)):107-115.
31. Mellquist J.L., Kasturi L., Spitalnik S.L., Shakin-Eshleman S.H. The amino acid following an asn-X-Ser/Thr sequon is an important determinant of N-linked core glycosylation efficiency. Biochemistry (Mosc) 1998, 37(May (19)):6833-6837.
32. Julius D., Blair L., Brake A., Sprague G., Thorner J. Yeast alpha factor is processed from a larger precursor polypeptide: the essential role of a membrane-bound dipeptidyl aminopeptidase. Cell 1983, 32(March (3)):839-852.
33. Sun J.B., Mielcarek N., Lakew M., Grzych J.M., Capron A., Holmgren J., et al. Intranasal administration of a Schistosoma mansoni glutathione S-transferase-cholera toxoid conjugate vaccine evokes antiparasitic and antipathological immunity in mice. J Immunol 1999, 163(July (2)):1045-1052.
34. Arakawa T., Yu J., Chong D.K., Hough J., Engen P.C., Langridge W.H. A plant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes. Nat Biotechnol 1998, 16(October (10)):934-938.
35. van Ginkel F.W., Jackson R.J., Yuki Y., McGhee J.R. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 2000, 165(November (9)):4778-4782.
36. Adamsson J., Lindblad M., Lundqvist A., Kelly D., Holmgren J., Harandi A.M. Novel immunostimulatory agent based on CpG oligodeoxynucleotide linked to the nontoxic B subunit of cholera toxin. J Immunol 2006, 176(April (8)):4902-4913.